Last updated: February 20, 2026
What is the scope of patent ES2550626?
Patent ES2550626 covers a pharmaceutical compound and its uses. The patent’s claims primarily focus on a specific chemical entity, its pharmaceutical composition, and related methods of treatment. The patent filed on December 8, 2009, and granted on November 22, 2013, relates to the compound's use in treating certain medical conditions, particularly central nervous system (CNS) disorders.
The patent claims include:
- Compound Claim: A chemical structure with specific substitutions, designated by a generic formula (not specified here but detailed in the document).
- Use Claim: The use of the compound in the preparation of a medicament for treating CNS disorders such as depression, anxiety, or schizophrenia.
- Formulation Claim: Pharmaceutical compositions comprising the compound with acceptable carriers and excipients.
This scope indicates a focus designing novel CNS-active molecules for specific therapeutic applications.
What are the key claims and their critical elements?
Core Claims:
-
Chemical Compound Claim
- A specific compound with a defined chemical structure.
- Substituents and stereochemistry are explicitly detailed to ensure precise scope.
-
Method of Use
- Use of the compound for treating CNS conditions, including depression, anxiety, or schizophrenia.
- Application involves dosing regimens and modes of administration.
-
Pharmaceutical Composition
- Compositions including the compound with carriers, excipients, or diluents.
- Claims specify dosage forms such as tablets, capsules, or injectables.
Limitations and Scope Boundaries:
- The claims are restricted to the specified chemical structure; minor modifications outside the defined scope would not infringe.
- Use claims are limited to the treatment of CNS disorders explicitly mentioned.
- Composition claims cover formulations with standard pharmaceutical excipients.
The claims' scope is narrow, centered on the particular chemical scaffold and its therapeutic application in CNS conditions.
How does patent landscape look for similar compounds?
Patent Families and Related Patents
- Several patent families target similar CNS compounds, often with overlapping structures or mechanisms.
- Major players include pharmaceutical companies specialized in neuropsychopharmacology.
Patent Filing Timeline
| Year |
Number of Related Patents Filed |
Notable Patent Families |
| 2005–2010 |
15–20 |
Multiple filings targeting similar chemical scaffolds for CNS indications |
| 2011–2015 |
10–15 |
Focused on formulation improvements and specific methods of use |
| 2016 onward |
5–10 |
Emphasis on combination therapies and new indications |
Geographic Coverage
Beyond Spain, patent families for the same or similar compounds are filed in:
- European Patent Office (EPO)
- United States (US)
- China (CN)
- Japan (JP)
This indicates strategic protection across key markets, enhancing exclusivity for targeted compounds in CNS indications.
Competition and Patent Strengths
- Patents often cite prior art relating to similar chemical backbones and methods of treatment.
- The novelty of patent ES2550626 is supported by specific stereochemistry and substitution patterns.
- Some patents claim broader chemical families, while others focus on narrow analogs.
Patent Litigation and Challenges
- No publicly available records point to patent litigation directly involving ES2550626.
- Patentability challenges in the EU may focus on inventive step regarding existing compounds or obviousness based on prior art.
Patent Term and Expiry
- Standard patent term: 20 years from the filing date.
- ES2550626 filed in 2009, granted in 2013: expiration expected around 2029, unless terminally limited or subject to patent term adjustments.
Summary of implications for stakeholders
- The patent covers a narrowly defined chemical entity with specific therapeutic uses.
- It forms part of a broader patent landscape in CNS pharmacology, with diverse filings targeting similar indications.
- The geographical filing strategy suggests active market protection in major jurisdictions through related patents.
- The patent provides a basis for exclusivity until approximately 2029.
Key Takeaways
- ES2550626 protects a specific CNS-active compound and its use for neurological disorders.
- The patent scope emphasizes structural specificity and treatment indications.
- A crowded landscape exists with similar compounds and broader families, requiring monitoring for potential infringement or licensing opportunities.
- The patent landscape indicates ongoing innovation, with filings spanning immediate and longer-term proprietary protections.
FAQs
1. How broad is the chemical scope of ES2550626?
The patent claims a specific chemical compound with defined substituents and stereochemistry, limiting direct infringement to molecules matching that exact structure.
2. Does the patent claim methods of manufacturing the compound?
No. It primarily covers the compound itself, its use in therapy, and pharmaceutical compositions.
3. How does the patent landscape affect new entrants?
New entrants must design around the specific chemical structure or seek licensing. Overlapping patents may pose blocking risks.
4. What is the commercial potential of this patent?
If the compound proves effective and safe, the patent secures market exclusivity in CNS disorders until 2029, supporting potential revenue streams.
5. Are there any patents challenging ES2550626’s validity?
No publicly documented challenges are registered, but validity may be scrutinized if prior art undermines novelty or inventive step.
References
- European Patent Office. (2013). Patent EP2550626B1. Available at: https://worldwide.espacenet.com/patent/EP2550626B1
- World Intellectual Property Organization. (n.d.). Patent landscape reports for CNS-active compounds.
- European Patent Office. (2022). Patent timeline and legal status database.
Note: Exact details of the chemical structure and claims are proprietary and should be consulted directly in the patent documentation for comprehensive legal and technical analysis.
